Systematic Review of Oral Janus Kinase Inhibitors in Alopecia Areata: Insights from 2020 to 2025 Studies

    Anna Mandecka, Kornela Kotucha-Cyl, Weronika Komala, Natalia Guzik, Joanna Gerlach, Dorota Plechawska, Joanna Kaźmierczak, Karolina Witek, Marta Nowocień
    Image of study
    TLDR Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
    The systematic review of studies from 2020 to 2025 on oral Janus kinase (JAK) inhibitors for alopecia areata reveals their promising efficacy and safety, particularly highlighting baricitinib, ritlecitinib, and deuruxolitinib as effective treatments for severe cases. Significant hair regrowth and manageable side effects were observed, with a notable phase 3 trial of deuruxolitinib showing positive results in adults. The review emphasizes the potential of JAK inhibitors as a viable treatment option, providing new hope for patients with alopecia areata.
    Discuss this study in the Community →

    Research cited in this study

    18 / 18 results

    Related Community Posts Join

    6 / 6 results

    Similar Research

    6 / 1000+ results